Accendra Health (NYSE: ACH) holders approve amended 2023 incentive plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Accendra Health, Inc. reported results from its 2026 Annual Meeting of Shareholders. Shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan, which replaces the prior 2023 plan and allows the Board’s Our People & Culture Committee to grant equity and other incentive awards to employees, non-employee directors and consultants.
At the meeting, 76,437,917 shares were entitled to vote and 62,134,133 shares were voted, representing approximately 81.29% participation. Six director nominees each received over 48.7 million votes for, including 51,189,677 votes for Teresa L. Kline, with detailed vote counts and broker non-votes reported for all proposals.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 5.07
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 76,437,917 shares
Shares voted: 62,134,133 shares
Voter participation: 81.29%
+3 more
6 metrics
Shares entitled to vote
76,437,917 shares
Common stock entitled to vote at 2026 Annual Meeting
Shares voted
62,134,133 shares
Shares voted in person or by proxy at the meeting
Voter participation
81.29%
Percentage of entitled shares that were voted
Votes for Teresa L. Kline
51,189,677 votes
Director election votes for nominee Teresa L. Kline
Votes for Edward A. Pesicka
48,760,777 votes
Director election votes for nominee Edward A. Pesicka
Broker non-votes (directors)
9,763,670 votes
Broker non-votes reported for each director proposal
Key Terms
Amended and Restated 2023 Omnibus Incentive Plan, Annual Meeting of Shareholders, broker non-votes, proxy statement, +1 more
5 terms
Amended and Restated 2023 Omnibus Incentive Plan financial
"shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan"
broker non-votes financial
"Mark A. Beck | 50,962,576 | 1,294,183 | 113,704 | 9,763,670"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
proxy statement regulatory
"included in the Company's proxy statement filed with the Securities and Exchange Commission on April 2, 2026"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
emerging growth company regulatory
"Emerging growth company ◻"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What is the Amended and Restated 2023 Omnibus Incentive Plan for Accendra Health (ACH)?
The Amended and Restated 2023 Omnibus Incentive Plan is an equity and incentive compensation program. It permits grants of stock-based and other awards to employees, non-employee directors and consultants, under agreements between Accendra Health and each award recipient.
Which board committee administers Accendra Health’s Amended and Restated 2023 Omnibus Incentive Plan?
The Our People & Culture Committee of Accendra Health’s Board administers the plan. The Board authorized this committee to grant equity and other incentive awards under the Amended and Restated 2023 Omnibus Incentive Plan to eligible participants.
Where can investors find more details on Accendra Health’s Amended and Restated 2023 Plan?
More detail appears in Accendra Health’s proxy statement filed April 2, 2026. The Form 8-K states that the description of the Amended and Restated 2023 Omnibus Incentive Plan in that proxy statement is incorporated by reference.